How many drugs treat Rhinitis?

Drug Landscape tracks 10 marketed treatments for Rhinitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/rhinitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rhinitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rhinitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rhinitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Flolan	EPOPROSTENOL	AstraZeneca	Prostacycline Vasodilator [EPC]	Prostacyclin receptor	1995-01-01
Bss	SODIUM CITRATE	B Braun	sodium citrate	Calcium	1980-01-01
Sudafed	pseudoephedrine	Generic (multiple manufacturers)	Nasal decongestant (sympathomimetic)	Alpha-1A adrenergic receptor, Alpha-2A adrenergic receptor, Beta-2 adrenergic receptor	1976-01-01
Sudafed PE	phenylephrine	Generic (multiple manufacturers)	Alpha-1 adrenergic agonist (decongestant/vasopressor)	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor	1976-01-01
Aminoacetic Acid 1.5% In Plastic Container	GLYCINE	Baxter	glycine	Olfactory receptor 51E2	1976-01-01
Delsym	dextromethorphan	Generic (originally Roche)	Antitussive (non-opioid)	Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6	1958-01-01
Synalgos-Dc	DIHYDROCODEINE	Caraco	Central Nervous System Stimulant [EPC]	Mu-type opioid receptor	1958-01-01
Mucinex	guaifenesin	Generic (multiple manufacturers)	Expectorant [EPC]	Vagal gastric reflex → increased respiratory secretions	1952-01-01
Phenergan Vc W/ Codeine	PHENYLEPHRINE BITARTRATE	ANI Pharmaceuticals	Nonsteroidal Anti-inflammatory Drug [EPC]	Alpha-1B adrenergic receptor	1952-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rhinitis:

Cite this brief

Drug Landscape (2026). Rhinitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rhinitis. Accessed 2026-06-10.

Rhinitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing